$INNV earnings report

InnovAge reported fiscal first-quarter 2027 total revenues of $264,757 (in thousands), net income of $20,878 (in thousands), and Adjusted EBITDA of $31,251 (in thousands), while confirming fiscal year 2027 guidance. AlphAI read InnovAge Holding's Fiscal first quarter 2027 filing as strong. 2 quarters are on record below.

Fiscal first quarter 2027

AlphAI · Earnings readINNV · Fiscal first quarter 2027 · ended September 30, 2026

InnovAge reported fiscal first-quarter 2027 total revenues of $264,757 (in thousands), net income of $20,878 (in thousands), and Adjusted EBITDA of $31,251 (in thousands), while confirming fiscal year 2027 guidance.

✓Strong quarter

Revenue increased approximately 12.1%, income before income taxes increased approximately 153.1%, Center-level Contribution Margin increased 23.8%, and Adjusted EBITDA increased by $13.6 million. Margins expanded across income before income taxes, net income, Center-level Contribution Margin, and Adjusted EBITDA.

Revenue
$265M
approximately 12.1% y/y
PACE
$265M
EPS · GAAP
$0.14
Fiscal year 2027 outlook
$1,050 to $1,085 (dollars in millions)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenues, three months ended September 30, 2026GAAP$264.8M–approximately 12.1%
Capitation revenue, three months ended September 30, 2026GAAP$264.7M––
Other service revenue, three months ended September 30, 2026GAAP$67K––
External provider costs, three months ended September 30, 2026GAAP$115.7M––
Cost of care, excluding depreciation and amortization, three months ended September 30, 2026GAAP$85.50M––
Sales and marketing expense, three months ended September 30, 2026GAAP$8.63M––
Corporate, general and administrative expense, three months ended September 30, 2026GAAP$29.15M––
Depreciation and amortization, three months ended September 30, 2026GAAP$5.66M––
Total expenses, three months ended September 30, 2026GAAP$244.6M––
Operating Income, three months ended September 30, 2026GAAP$20.15M––
Interest expense, net, three months ended September 30, 2026GAAP−$123K––
Other income, net, three months ended September 30, 2026GAAP$10K––
Income Before Income Taxes, three months ended September 30, 2026GAAP$20.04M–approximately 153.1%
Income Before Income Taxes as a percent of revenue, three months ended September 30, 2026GAAP7.6%–an increase of 4.2 percentage points
Provision (Benefit) for Income Taxes, three months ended September 30, 2026GAAP−$841K––
Net Income, three months ended September 30, 2026GAAP$20.88M––
Net Income margin, three months ended September 30, 2026GAAP7.9%–an increase of 4.6 percentage points
Net Income Attributable to InnovAge Holding Corp., three months ended September 30, 2026GAAP$19.55M––
Net loss per share - basic, three months ended September 30, 2026GAAP$0.14––
Net loss per share - diluted, three months ended September 30, 2026GAAP$0.14––
Center-level Contribution Margin, three months ended September 30, 2026non-GAAP$63.59M–23.8%
Center-level Contribution Margin as a % of revenue, three months ended September 30, 2026non-GAAP24.0%–an increase of 2.2 percentage points
Adjusted EBITDA, three months ended September 30, 2026non-GAAP$31.25M–an increase of $13.6 million
Adjusted EBITDA margin, three months ended September 30, 2026non-GAAP11.8%–an increase of 4.3 percentage points
Census, fiscal first quarter 2027otherapproximately 8,420 participants––
Member months, fiscal first quarter 2027otherapproximately 25,070––
Net cash provided by operating activities, three months ended September 30, 2026GAAP$28.74M––
Net cash used in investing activities, three months ended September 30, 2026GAAP−$3.42M––
Purchases of property and equipment, three months ended September 30, 2026GAAP−$2.99M––
Net cash used in financing activities, three months ended September 30, 2026GAAP−$3.96M––
Cash and cash equivalents as of September 30, 2026GAAP$119.3M––
Short-term investments as of September 30, 2026GAAP$43.74M––
Debt on the balance sheet at the end of fiscal first quarter 2027GAAP$61.4M––

Segments

SegmentRevenueq/qy/y
PACEPACE capitation revenue was $264,690 (in thousands).$264.8M––
All otherThe prior-year all other revenue was $257 (in thousands), primarily attributable to the Senior Housing operating segment, whose assets were sold on September 11, 2025.$— (in thousands)––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Fiscal year 2027 outlook

  • Revenue$1,050 to $1,085 (dollars in millions)
  • NoteCensus: 8,625 to 8,850
  • NoteTotal Member Months: 101,000 to 102,500
  • NoteAdjusted EBITDA: $105 to $115 (dollars in millions, non-GAAP)

What drove it

  • Continued census growth and disciplined clinical and operational execution were cited as drivers of financial performance.
  • Census was approximately 8,420 participants, compared with 7,890 participants in the first quarter of fiscal year 2026.
  • Member months were approximately 25,070, compared with 23,500 in the first quarter of fiscal year 2026.
  • Center-level Contribution Margin increased 23.8% to $63,587 (in thousands), and its margin increased 2.2 percentage points to 24.0%.
  • Corporate, general and administrative expense was $29,149 (in thousands), compared with $30,273 (in thousands).
  • Interest expense, net was $(123) (in thousands), compared with $(1,251) (in thousands).

Concerns

  • The Company stated that expected results and estimates may be impacted by factors outside its control and actual results may be materially different from guidance.
  • Business optimization expense was $1,707 (in thousands), including $1.5 million related to organizational restructure and executive severance and $0.2 million related to closure of the previously planned de novo center in Downey, California.
  • Offering expenses were $1,679 (in thousands) related to filing and legal fees for the Form S-3 Shelf Registration Statement and subsequent secondary offering.
  • The forward-looking statement disclosures identify risks including reductions in PACE reimbursement rates, Medicaid budget reductions, healthcare cost inflation, labor shortages, and government-program reviews, audits and investigations.

What to watch

  • Progress toward fiscal year 2027 census guidance of 8,625 to 8,850 and Total Member Months guidance of 101,000 to 102,500.
  • Execution against fiscal year 2027 total revenues guidance of $1,050 to $1,085 and Adjusted EBITDA guidance of $105 to $115.
  • Whether Center-level Contribution Margin and Adjusted EBITDA margins sustain the fiscal first-quarter levels of 24.0% and 11.8%, respectively.
  • Cash generation following $28,742 (in thousands) of net cash provided by operating activities in the fiscal first quarter.
  • The effect of business optimization, organizational restructure and executive severance costs, and costs related to the Downey, California center closure.

Balance sheet and cash flow

  • Cash and cash equivalents were $119,253 (in thousands) as of September 30, 2026, compared with $97,891 (in thousands) as of June 30, 2026.
  • Short-term investments were $43,740 (in thousands) as of September 30, 2026, compared with $43,435 (in thousands) as of June 30, 2026.
  • The Company reported $61.4 million in debt, representing debt under its senior secured term loan, revolving credit facility and finance lease obligations.
  • Net cash provided by operating activities was $28,742 (in thousands), compared with $3,924 (in thousands).
  • Net cash used in investing activities was $(3,425) (in thousands), including purchases of property and equipment of $(2,988) (in thousands).
  • Net cash used in financing activities was $(3,956) (in thousands).

Analysis

InnovAge began fiscal 2027 with $264,757 (in thousands) of total revenues, compared with $236,105 (in thousands) in the fiscal first quarter of 2026. The Company characterized the increase as approximately 12.1%. Census rose to approximately 8,420 participants from 7,890 participants, while member months rose to approximately 25,070 from 23,500. Capitation revenue was $264,690 (in thousands), comprising nearly all reported revenue.

Profitability increased materially. Income Before Income Taxes was $20,037 (in thousands), compared with $7,916 (in thousands), an approximately 153.1% increase. Its percentage of revenue was 7.6%, up 4.2 percentage points from 3.4%. Net Income was $20,878 (in thousands), compared with $7,669 (in thousands), and Net Income margin was 7.9%, up 4.6 percentage points. Net Income Attributable to InnovAge Holding Corp. was $19,553 (in thousands), or $0.14 per basic and diluted share, compared with $8,019 (in thousands), or $0.06 per share.

Non-GAAP operating measures also strengthened. Center-level Contribution Margin was $63,587 (in thousands), up 23.8% from $51,356 (in thousands), and its margin reached 24.0% from 21.8%. Adjusted EBITDA was $31,251 (in thousands), compared with $17,642 (in thousands), while Adjusted EBITDA margin increased to 11.8% from 7.5%. Corporate, general and administrative expense declined to $29,149 (in thousands) from $30,273 (in thousands), although the quarter included $1,707 (in thousands) of business optimization expense and $1,679 (in thousands) of offering expenses in the Adjusted EBITDA reconciliation.

Cash generation improved, with net cash provided by operating activities of $28,742 (in thousands), compared with $3,924 (in thousands). Cash and cash equivalents were $119,253 (in thousands) and short-term investments were $43,740 (in thousands) at September 30, 2026. InnovAge confirmed fiscal year 2027 guidance, including total revenues of $1,050 to $1,085 and Adjusted EBITDA of $105 to $115, both stated in dollars in millions. Management said that, effective in fiscal year 2027, prepared remarks will emphasize year-over-year performance rather than previously reported sequential-quarter comparisons.

Management, verbatim

We are pleased with our strong stat to fiscal 2027, as continued census growth along with disciplined clinical and operational execution drove strong financial performance.

Patrick Blair, Chief Executive Officer of InnovAge

Not in the filing

stated, not guessed
  • Gross margin was not reported.
  • Free cash flow was not reported.
  • Share repurchases and dividends were not reported.
  • Guidance for gross margin, operating expenses and tax rate was not provided.
  • Quarterly sequential comparisons were not reported in the financial-results discussion.
  • Formal reportable-segment operating income was not reported.
  • The previous outlook covered the full fiscal year 2027 only, and this release reports the first quarter, so there is nothing to compare for this period.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Fourth quarter and fiscal year 2026

AlphAI · Earnings readINNV · Fourth quarter and fiscal year 2026 · ended June 30, 2026

InnovAge reported fiscal 2026 revenue of $989.7 million and Adjusted EBITDA of $94.6 million, while fourth-quarter net income attributable to InnovAge Holding Corp. was $8.3 million.

→Mixed quarter

Revenue, Center-level Contribution Margin and Adjusted EBITDA increased materially in fiscal 2026, and the fourth quarter returned to GAAP profitability. Fiscal-year net income remained a loss of $(683) thousand, including $56,966 thousand of litigation costs and settlements added back in Adjusted EBITDA.

Revenue
$262M
PACE, fiscal 2026
$989M
EPS · GAAP
$ 0.06
Full Fiscal Year 2027 outlook
$ 1,050 to $ 1,085 (dollars in millions)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q4 total revenues (in thousands)GAAP$262.0M––
Fiscal 2026 total revenues (in thousands)GAAP$989.7M–increased approximately 15.9%
Q4 capitation revenue (in thousands)GAAP$261.5M––
Fiscal 2026 capitation revenue (in thousands)GAAP$988.4M––
Q4 other service revenue (in thousands)GAAP440K––
Fiscal 2026 other service revenue (in thousands)GAAP1.32M––
Q4 external provider costs (in thousands)GAAP115.7M––
Fiscal 2026 external provider costs (in thousands)GAAP449.8M––
Q4 cost of care, excluding depreciation and amortization (in thousands)GAAP83.65M––
Fiscal 2026 cost of care, excluding depreciation and amortization (in thousands)GAAP312.1M––
Q4 sales and marketing (in thousands)GAAP9.93M––
Fiscal 2026 sales and marketing (in thousands)GAAP34.36M––
Q4 corporate, general and administrative (in thousands)GAAP33.08M––
Fiscal 2026 corporate, general and administrative (in thousands)GAAP166.5M––
Q4 depreciation and amortization (in thousands)GAAP6.36M––
Fiscal 2026 depreciation and amortization (in thousands)GAAP21.14M––
Q4 impairments and loss on assets held for sale (in thousands)GAAP3.05M––
Fiscal 2026 impairments and loss on assets held for sale (in thousands)GAAP3.15M––
Q4 operating income (loss) (in thousands)GAAP10.15M––
Fiscal 2026 operating income (loss) (in thousands)GAAP2.62M––
Q4 interest expense, net (in thousands)GAAP−772K––
Fiscal 2026 interest expense, net (in thousands)GAAP−4.26M––
Q4 other income, net (in thousands)GAAP293K––
Fiscal 2026 other income, net (in thousands)GAAP1.91M––
Q4 income (loss) before income taxes (in thousands)GAAP9.67M––
Fiscal 2026 income (loss) before income taxes (in thousands)GAAP266K–increased by 100.8%
Q4 provision for income taxes (in thousands)GAAP−116K––
Fiscal 2026 provision for income taxes (in thousands)GAAP949K––
Q4 net income (loss) (in thousands)GAAP9.78M––
Fiscal 2026 net income (loss) (in thousands)GAAP−683K–decreased 98%
Q4 net income (loss) marginGAAP3.7 %––
Fiscal 2026 net income (loss) marginGAAP(0.1) %–increased 4.1 percentage points
Q4 net income (loss) attributable to InnovAge Holding Corp. (in thousands)GAAP$8.29M––
Fiscal 2026 net income (loss) attributable to InnovAge Holding Corp. (in thousands)GAAP−$2.54M––
Q4 net loss per share - basicGAAP$ 0.06––
Q4 net loss per share - dilutedGAAP$ 0.06––
Fiscal 2026 net loss per share - basicGAAP$ (0.02)––
Fiscal 2026 net loss per share - dilutedGAAP$ (0.02)––
Q4 Center-level Contribution Margin (in thousands)non-GAAP$62.56M––
Fiscal 2026 Center-level Contribution Margin (in thousands)non-GAAP$227.8M–increased 48.3%
Q4 Center-level Contribution Margin as a percent of revenuenon-GAAP23.9 %––
Fiscal 2026 Center-level Contribution Margin as a percent of revenuenon-GAAP23.0 %–increased 5.0 percentage points
Q4 Adjusted EBITDA (in thousands)non-GAAP24.28M––
Fiscal 2026 Adjusted EBITDA (in thousands)non-GAAP94.57M–an increase of $60.1 million
Q4 Adjusted EBITDA marginnon-GAAP9.3 %––
Fiscal 2026 Adjusted EBITDA marginnon-GAAP9.6 %–an increase of 5.5 percentage points
Fiscal 2026 censusotherapproximately 8,230 participants––
Fiscal 2026 member monthsotherapproximately 96,050––

Segments

SegmentRevenueq/qy/y
PACE, fiscal 2026Capitation revenue was $ 988,384 and other service revenue was 1,066.$989.5M––
All other, fiscal 2026Center-level Contribution Margin from this segment was attributable to the Senior Housing operating segment.257K––
PACE, Q4 2026Capitation revenue was $ 261,511 and other service revenue was 440.$262.0M––
All other, Q4 2026The filing reports no All other revenue for the quarter.—––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Full Fiscal Year 2027 outlook

  • Revenue$ 1,050 to $ 1,085 (dollars in millions)
  • NoteCensus: 8,625 to 8,850
  • NoteTotal Member Months: 101,000 to 102,500
  • NoteAdjusted EBITDA: 105 to 115 (dollars in millions), non-GAAP

Capital returns

  • Repurchase of equity securities: — for fiscal 2026; $(7,321) for fiscal 2025 (in thousands).
  • No dividend was reported.

What drove it

  • Fiscal 2026 total revenues increased approximately 15.9% to $989.7 million.
  • Fiscal 2026 Center-level Contribution Margin increased 48.3% to $227.8 million and its margin increased 5.0 percentage points to 23.0%.
  • Fiscal 2026 Adjusted EBITDA increased by $60.1 million to $94.6 million and Adjusted EBITDA margin increased 5.5 percentage points to 9.6%.
  • Fiscal 2026 census was approximately 8,230 participants and member months were approximately 96,050.
  • Q4 2026 operating income was 10,146 (in thousands), compared with an operating loss of (2,150) (in thousands) in Q4 2025.

Concerns

  • Fiscal 2026 net income (loss) was $(683) thousand and net income (loss) attributable to InnovAge Holding Corp. was $(2,537) thousand.
  • Fiscal 2026 corporate, general and administrative expense was 166,489 (in thousands), compared with 122,058 (in thousands) in fiscal 2025.
  • Litigation costs and settlements added back in fiscal 2026 Adjusted EBITDA were 56,966 (in thousands), including an aggregate $52.4 million of accrued loss for potential resolutions or paid settlements.
  • Q4 2026 included 3,050 (in thousands) of impairments and loss on assets held for sale, including impairment charges related to a previously planned de novo center in Downey, California.
  • The company identified risks including PACE reimbursement-rate reductions, government funding reductions, labor shortages, the risk that service costs exceed compensation, audits and investigations, and legal proceedings.

What to watch

  • Execution against full fiscal year 2027 guidance for census of 8,625 to 8,850 and Total Member Months of 101,000 to 102,500.
  • Execution against full fiscal year 2027 total revenue guidance of $ 1,050 to $ 1,085 (dollars in millions) and Adjusted EBITDA guidance of 105 to 115 (dollars in millions).
  • Whether the company sustains Center-level Contribution Margin and Adjusted EBITDA margins following fiscal 2026 levels of 23.0% and 9.6%, respectively.
  • Future litigation costs, settlements and accrued losses, which were a material Adjusted EBITDA reconciliation item in fiscal 2026.
  • PACE reimbursement, government payor funding and the cost of providing services under PACE contracts.

Balance sheet and cash flow

  • Cash and cash equivalents: $ 97,891 as of June 30, 2026, compared with $ 64,129 as of June 30, 2025 (in thousands).
  • Short-term investments: 43,435 as of June 30, 2026, compared with 41,775 as of June 30, 2025 (in thousands).
  • Long-term debt, net of debt issuance costs: 45,521 as of June 30, 2026, compared with 57,464 as of June 30, 2025 (in thousands).
  • Current portion of long-term debt: 2,536 as of June 30, 2026, compared with 2,250 as of June 30, 2025 (in thousands).
  • Net cash provided by operating activities: 64,714 for fiscal 2026, compared with 32,866 for fiscal 2025 (in thousands).
  • Purchases of property and equipment: (14,309) for fiscal 2026, compared with (6,263) for fiscal 2025 (in thousands).
  • Net cash used in investing activities: (12,340) for fiscal 2026, compared with (5,550) for fiscal 2025 (in thousands).
  • Net cash used in financing activities: (18,531) for fiscal 2026, compared with (19,082) for fiscal 2025 (in thousands).
  • Cash, cash equivalents and restricted cash, end of period: $ 97,901 for fiscal 2026, compared with $ 64,140 for fiscal 2025 (in thousands).

Analysis

InnovAge closed fiscal 2026 with revenue of $989.7 million, up approximately 15.9% from $853.7 million, while census reached approximately 8,230 participants and member months reached approximately 96,050. The fourth quarter produced $261,951 thousand of total revenues, compared with $221,417 thousand in the prior-year quarter and $251,943 thousand in the quarter ended March 31, 2026. PACE represented $989,450 thousand of fiscal-year revenue, while the All other segment contributed 257 thousand.

The core operating measures improved substantially. Fiscal-year Center-level Contribution Margin rose to $227.8 million from $153.6 million, and the corresponding margin increased to 23.0% from 18.0%. Adjusted EBITDA increased to $94.6 million from $34.5 million, with margin increasing to 9.6% from 4.0%. In the fourth quarter, Center-level Contribution Margin was $62,562 thousand and Adjusted EBITDA was $24,282 thousand, compared with $41,287 thousand and $11,326 thousand, respectively, a year earlier.

GAAP profitability improved but was not fully established for the year. Fourth-quarter operating income was $10,146 thousand and net income was $9,783 thousand, compared with an operating loss of $(2,150) thousand and net loss of $(5,009) thousand in the prior-year quarter. Fiscal-year operating income was $2,618 thousand, but fiscal-year net loss was $(683) thousand. The reconciliation shows $56,966 thousand of litigation costs and settlements added back to fiscal 2026 Adjusted EBITDA, including an aggregate $52.4 million of accrued loss for potential resolutions or paid settlements.

Cash generation strengthened, with net cash provided by operating activities of $64,714 thousand versus $32,866 thousand in fiscal 2025. Cash and cash equivalents ended fiscal 2026 at $97,891 thousand, while long-term debt, net of debt issuance costs, was $45,521 thousand. The company also made $71,282 thousand of principal payments on long-term debt and had $60,082 thousand of proceeds from long-term debt during the year.

For full fiscal year 2027, InnovAge guided to census of 8,625 to 8,850, Total Member Months of 101,000 to 102,500, total revenues of $ 1,050 to $ 1,085 (dollars in millions), and Adjusted EBITDA of 105 to 115 (dollars in millions). The company did not provide net income guidance or an Adjusted EBITDA reconciliation, citing the difficulty of forecasting items including effective tax-rate variation, acquisition activity expenses and other one-time or exceptional items.

Management, verbatim

Fiscal 2026 was an exceptional year for InnovAge and reflects the significant progress we have made strengthening the company.

Patrick Blair, Chief Executive Officer of InnovAge

We enter Fiscal 2027 in a strong position, with a durable foundation to serve more seniors and to deliver high-quality care. We remain focused on disciplined execution and creating sustainable long-term value for all of our stakeholders.

Patrick Blair, Chief Executive Officer of InnovAge

Not in the filing

stated, not guessed
  • Prior outlook was not provided, so comparison of actual results with prior guidance is unavailable.
  • Gross margin was not reported.
  • Gross-margin guidance was not reported.
  • Operating-expense guidance was not reported.
  • Tax-rate guidance was not reported.
  • Free cash flow was not reported.
  • Dividend amount and dividend policy were not reported.
  • A quantitative year-over-year or quarter-over-quarter change was not printed for several individual income-statement line items and segment revenues.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about INNV earnings dates

When is InnovAge Holding's next earnings date?
AlphAI has no date for INNV yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.